Targeting triple negative breast cancer with histone deacetylase inhibitors

References

• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–1948.
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434.
   PubMed Web of Science ®Google Scholar
• Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9(2):S73–S81.
   PubMed Web of Science ®Google Scholar
• Le Du F, Ueno NT. Targeted therapies in triple-negative breast cancer: failure and future. Womens Health. 2015;11(1):1–5.
   Web of Science ®Google Scholar
• Fedele P, Calvani N, Marino A, et al. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we and where are we going? Crit Rev in Onc Hemat. 2012;84:243–251.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205–214.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2011;29(Suppl):abstr 1007.
   Google Scholar
• O’Shaughnessy J, Romieu G, Diéras V, et al. Meta-analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res. 2010;70(Suppl24):P6-12-03.
   Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–2676.
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239–3247.
   PubMed Web of Science ®Google Scholar
• Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14(10):933–942.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Pivot X, Cortés J, et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast. 2013;22(5):650–656.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Kaklamani V, Sahoo TP, et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer. 2013;49(2):312–322.
   PubMed Web of Science ®Google Scholar
• Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized Phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30(21):2615–2623.
   PubMed Web of Science ®Google Scholar
• Yunokawa M, Koizumi F, Kitamura Y, et al. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci. 2012;103(9):1665–1671.
   PubMed Web of Science ®Google Scholar
• Fornier MN, Morris PG, Abbruzzi A, et al. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol. 2011;22:2575–2581.
   PubMed Web of Science ®Google Scholar
• Finn RS, Bengala C, Ibrahim N et al. Phase II trial of dasatinib in triple negative breast cancer: results of study CA180059. Proceedings of the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 10–14, 2008, San Antonio, TX; AACR Philadelphia, PA: Abstr 3118.
   Google Scholar
• Gucalp A, Tolaney S, Isakoff SJ, et al. Trial of bicalutamide in patients with androgen receptor positive, estrogen receptor negative metastatic breast cancer. Cancer Res. 2013;19:5505–5512.
   Web of Science ®Google Scholar
• Librizzi M, Longo A, Chiarelli R, et al. ChCytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells. Em Res Toxicol. 2012;25(11):2608–2616.
   PubMed Web of Science ®Google Scholar
• Bustos MA, Salomon MP, Nelson N, et al. Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer. Genom Data. 2017;12:14–16.
   PubMed Web of Science ®Google Scholar
• Crown J, O’Shaughnessy J, Gullo G, et al. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol. 2012;23(Supplement 6):vi56–vi65.
   PubMed Web of Science ®Google Scholar
• Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349–352.
   PubMed Web of Science ®Google Scholar
• Glozak MA, Sengupta N, Zhang X, et al. Acetylation and deacetylation of non-histone proteins. Gene. 2005;363:15–23.
   PubMed Web of Science ®Google Scholar
• Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets. 2005;9(4):809–824.
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541–5552.
   PubMed Web of Science ®Google Scholar
• Liu T, Kuljaca S, Tee A, et al. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev. 2006;32:157–165.
   PubMed Web of Science ®Google Scholar
• Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002;21:427–436.
   PubMed Web of Science ®Google Scholar
• Rhodes LV, Tate CR, Segar HC, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat. 2014;145(3):593–604.
   PubMed Web of Science ®Google Scholar
• Rangel MC, Bertolette D, Castro NP. Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer. Breast Cancer Res Treat. 2016;156(2):211–226.
   PubMed Web of Science ®Google Scholar
• Setiadi AF, Omilusik K, David MD, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 2008;68:9601–9607.
   PubMed Web of Science ®Google Scholar
• Woods DM, Woan K, Cheng F, et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013;23:341–348.
   PubMed Web of Science ®Google Scholar
• Chou SD, Khan AN. Magner WJ and Tomasi TB. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int Immunol. 2005;17:1483–1494.
   PubMed Web of Science ®Google Scholar
• Soady KJ, Kendrick H, Gao Q. Mouse mammary stem cells express prognostic markers for triple negative breast cancer. Breast Cancer Research. 2015;17:2–23.
   PubMed Web of Science ®Google Scholar
• Sulaiman A, Sulaiman B, Khouri L, et al. Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERα coinhibition. FEBS Lett. 2016;590(24):4606–4616.
   PubMed Web of Science ®Google Scholar
• Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69:1302–1313.
   PubMed Web of Science ®Google Scholar
• Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672–679.
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284.
   PubMed Web of Science ®Google Scholar
• Gangemi R, Paleari L, Orengo AM, et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem. 2009;16:1688–1703.
   PubMed Web of Science ®Google Scholar
• Kai M, Kanaya N, Wu Shang V, et al. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin. Breast Cancer Res Treat. 2015;151:281–294.
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Gibbons DL, Kurie JM, et al. The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res. 2013;5:187–195.
   PubMedGoogle Scholar
• Kashiwagi S, Yashiro M, Takashima T, et al. Significance of e-cadherin expression in triple-negative breast cancer. Br J Cancer. 2010;103:249–255.
   PubMed Web of Science ®Google Scholar
• Gregoire JM, Fleury L, Salazar-Cardozo C, et al. Identification of epigenetic factors regulating the mesenchyme to epithelium transition by RNA interference screening in breast cancer cells. BMC Cancer. 2016;700:4–11.
   Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–2767.
   PubMed Web of Science ®Google Scholar
• Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688–1698.
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244–250.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial expansion cohort of the PARP inhibitor veliparib (ABT888) and temozolomide in BRCA1/2 associated metastatic breast cancer. Cancer Res. 2011;71:P3-16-05.
   Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–244.
   PubMed Web of Science ®Google Scholar
• Taselisib and enzalutamide in treating patients with androgen receptor positive triple negative metastatic breast cancer. [cited 2017 Sep 26]. Available from: https://clinicaltrials.gov/ct2/results?term=NCT02457910&Search=Search. Identifier: NCT02457910.
   Google Scholar
• Sharpe R, Pearson A, Herrera-Abreu MT, et al. FGFR signalling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2011;17:5275–5286.
   PubMed Web of Science ®Google Scholar
• Ye T, Wei X, Yin T, et al. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Res Treat. 2014;143:435–446.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple negative breast cancer; phase Ib Keynote-012. J Clin Oncol. 2016;34:2460–2467.
   PubMed Web of Science ®Google Scholar
• Study of Pembrolizumab (MK-3475) monotherapy for metastatic triple negative breast cancer (Mk-3475-086/Keynote-086). [cited 2017 Sep 26]. Available from: https://clinicaltrials.gov/ct2/results?term=NCT02447003
   Google Scholar
• Study of single agent pembrolizumab (MK-3475) versus single agent chemotherapy for metastatic triple negative breast cancer (MK-3475-119/KEYNOTE-119). [cited 2017 Sep 26]. Available from: https://clinicaltrials.gov/ct2/results?term= NCT02555657
   Google Scholar
• A study of atezolizumab in combination with Nab-Paclitaxel compared with placebo with Nab-Paclitaxel for participants with previously untreated metastatic triple negative breast cancer (IMpassion130). [cited 2017 Sep 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02425891
   Google Scholar
• De Ruijter AJ, Van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737–749.
   PubMed Web of Science ®Google Scholar
• Song J, Noh JH, Lee JH, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. Apmis. 2005;113:264–268.
   PubMed Web of Science ®Google Scholar
• Cao C, Vasilatos SN, Bhargava R, et al. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase I (LSD1) promotes breast cancer progression. Oncogene. 2016. Epub ahead of print. DOI:10.1038/onc.2016.186.
   Web of Science ®Google Scholar
• Rajneesh P, Sabarish R, Gurusamy M, et al. Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem like cells and attenuates mammary tumor growth. Cancer Res. 2016;76:3224–3235.
   PubMed Web of Science ®Google Scholar
• Legarè S, Basik M. Minireview: the link between ERα corepressors and histone deacetylases in tamoxifen resistance in breast cancer. Mol Endocrinol. 2016;30:965–976.
   PubMed Web of Science ®Google Scholar
• Reid G, Metivier R, Lin CY, et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene. 2005;24:4894–4907.
   PubMed Web of Science ®Google Scholar
• Hirokawa Y, Arnold M, Nakajima H, et al. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther. 2005;4:956–960.
   PubMed Web of Science ®Google Scholar
• Jang ER, Lim SJ, Lee ES, et al. The histone deacetylase inhibitor trichostatin a sensitizes estrogen receptor α- negative breast cancer cells to tamoxifen. Oncogene. 2004;23:1724–1736.
   PubMed Web of Science ®Google Scholar
• Duong V, Licznar A, Margueron R, et al. ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene. 2006;25:1799–1806.
   PubMed Web of Science ®Google Scholar
• Stark K, Burger A, Wu J, et al. Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal like triple negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor. Plos One. 2013;8:e74525.
   PubMed Web of Science ®Google Scholar
• de Cremoux P, Dalvai M, N’Doye O, et al. HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts. Breast Cancer Res Treat. 2015;149(1):81–89.
   PubMed Web of Science ®Google Scholar
• Grant S, Dai Y. Histone deacetylase inhibitors and rational combination therapies. Adv Cancer Res. 2012;116:199–237.
   PubMed Web of Science ®Google Scholar
• Cao ZA, Bass KE, Balasubramaniam S, et al. CRA-026440: a potent, broad spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Mol Cancer Ther. 2006;5:1693–1701.
   PubMed Web of Science ®Google Scholar
• Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005;11:1–15.
   PubMed Web of Science ®Google Scholar
• Villagra A, Cheng F, Wang HW, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009;10:92–100.
   PubMed Web of Science ®Google Scholar
• Proesen M. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget. 2014;16:6558–6572.
   Google Scholar
• Tate CR, Rhodes LV, Segar HC, et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14(3):R79.
   PubMed Web of Science ®Google Scholar
• Lyndsay V. Rhodes, Chandra R, Segar HC, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat. 2014;145:593–604.
   PubMed Web of Science ®Google Scholar
• Rao R, Balusu R, Fiskus W, et al. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 2012;11:973–983.
   PubMed Web of Science ®Google Scholar
• Schech A, Kazi A, Yu S, et al. Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells. Mol Cancer Ther. 2015;14:1848–1857.
   PubMed Web of Science ®Google Scholar
• Yang X, Phillips DL, Ferguson AT, et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001;61:7025–7029.
   PubMed Web of Science ®Google Scholar
• Stark K, Burger A, Wu J, et al. Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor. Cancer PLoS One. 2013;8:e74525.
   PubMed Web of Science ®Google Scholar
• Palmieri D, Lockman PR, Thomas FC, et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res. 2009;15:6148–6157.
   PubMed Web of Science ®Google Scholar
• Wawruszak A, Luszczki JJ, Grabarska A, et al. Assessment of interactions between cisplatin and two histone deacetylase inhibitors in MCF7, T47D and MDA-MB-231 human breast cancer cell lines - an isobolographic analysis. PLoS One. 2015;18:e0143013.
   Google Scholar
• Min A, Im SA. Kim DK Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res. 2015;17:33.
   PubMed Web of Science ®Google Scholar
• Tan WW, Allred JB, Moreno-Aspitia A, et al. Phase I study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients. Clin Breast Cancer. 2016;16:82–86.
   PubMed Web of Science ®Google Scholar
• Tu Y, Hershman DL, Bhalla K, et al. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014;146:145–152.
   PubMed Web of Science ®Google Scholar
• Entinostat and anastrozole in treating postmenopausal women with triple-negative breast cancer that can be removed by surgery. [cited 2017 Sep 26]. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01234532
   Google Scholar
• ENCORE 602: A randomized, placebo-controlled, double-blind, multicenter phase 2 study of atezolizumab with or without entinostat in patients with advanced triple negative breast cancer, with a phase 1b lead in phase. [cited 2017 Sep 26]. Available from: https://clinicaltrials.gov/ct2/results?term=NCT02708680
   Google Scholar